Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Strategy Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Strategy Inc. trades at $97.61 (market cap $38.33B). The key difference: Strategy Inc. is far larger — about 7.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | MSTR | |
|---|---|---|
Market Cap | $5.06B | $38.33B |
Sector | Health | Technology |
52-Week High | $29.41 | $394.39 |
52-Week Low | $20.06 | $82.31 |
Enterprise Value | $4.18B | $57.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSTR trades at $100.01, up 3.26% today, with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 EPS of -$24.45 versus -$2.19 expected, continuing a trend of negative profitability. Analyst consensus remains positive with a $210 price target, though fundamentals show significant challenges including a negative net income margin of -6,102.96% and substantial Bitcoin-related investment outflows.
The outlook is mixed: strong analyst support suggests upside potential, but fundamental weaknesses and persistent earnings misses pose substantial risks. Investment opportunity exists if the company can leverage its cash position for growth, while risks include continued operational losses and dependence on Bitcoin market performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
